MGX · Metagenomi Therapeutics, Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on MGX. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About MGX · Metagenomi Therapeutics, Inc.
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs. The company was formerly known as Metagenomi, Inc. and changed its name to Metagenomi Therapeutics, Inc. in January 2026. Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.
Live Quote
SELL (score -8) · 12-1 mom -14.9% · RSI 45.8 · below_both · -63.0% from high
Targets blend Wall Street consensus (2 analysts: low $7.00 / mean $8.00 / high $9.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
Metagenomi Therapeutics is a pre-commercial in vivo genome editing biotech (Nasdaq: MGX) with lead program MGX-001 for hemophilia. The investigation trigger was flagged on the basis of 3 Form 4 filings in 14 days, but upon reading every filing text, all transactions from the recent window were either RSU vesting grants (code A at $0 strike — not open-market purchases) or tax-withholding sales (code S). There is no genuine insider conviction-buying signal here. The stock is down ~68% from its 52-week high of $3.95 and near the lows at $1.26, below both the 50- and 200-day MAs with bearish MACD cross. No options market exists (options_expiries returned empty), eliminating income or structured-product plays. Q1 revenue collapsed to $1.2M vs. $4.1M YoY — a -68% miss — while quarterly cash burn runs ~$21M. The IND submission for MGX-001 is not expected until Q4 2026, creating an 18-month data gap. No mispricing, no tradable options, and all apparent insider 'cluster' is compensation administration rather than directional conviction.